1 North Waukegan Road
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
People. Passion. Possibilities. Those three simple words mean everything at AbbVie, where patients always come first. So do cutting-edge science and innovation, which fuel our expanding pipeline as we take on the world's toughest health challenges in oncology, immunology, liver disease, women's health and beyond. Together, we strive to make a difference for patients around the world. For more visit: www.abbvie.com.
945 articles with AbbVie
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
The M&A moves are expected to increase the oncology pipelines of both companies.
AbbVie, a research-based global biopharmaceutical company, will announce its second-quarter 2019 financial results on Friday, July 26 before the market opens.
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
CytomX Therapeutics, Inc. announced the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
AbbVie issued the following forms
Humira generates about 60% of AbbVie's annual revenue but is expected to lose patent protection in 2023.
Provides immediate scale and profitability to AbbVie's growth platform, excluding Humira, significantly expanding and diversifying its revenue base with new therapeutic areas, including Allergan's leading medical aesthetics business
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Allergan Plc in connection with the proposed acquisition of the Company by AbbVie Inc..
The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company's long-term reliance on its cash cow, Humira.
AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality
- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria
The partial clinical hold was lifted after the company revised the study protocol for the trial. The partial clinical hold remains on other multiple myeloma trials involving venetoclax.
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.07 per share.
EndBrainCancer Initiative Announced Campaign for New Brain Cancer Clinical Trials in the Greater Puget Sound Area at its Education, Awareness & Action Dinner
The EndBrainCancer Initiative held its 8th Annual "Brains Matter" Dinner on May 15th raising $57,500 for its work.
New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR
Data from SELECT-EARLY and SELECT-COMPARE show a significantly higher proportion of patients treated with upadacitinib monotherapy or in combination with methotrexate (MTX) maintaining clinical remission compared with MTX or adalimumab plus MTX, respectively, at 48 weeks
New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance
Longer-term results from IMMhance showed 73 percent and 72 percent of patients treated with continuous SKYRIZI™ (risankizumab) experienced complete skin clearance (defined as sPGA 0 and PASI 100, respectively) at week 94, among patients who achieved sPGA 0/1 at week 28
Approximately 9,000 employees participate in volunteer activities to update schools and community centers all over the world benefitting more than 70,000 students and 50,000 community members
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019. Michael Severino, vice chairman and president, will present at 10:00 a.m. Central time.
According to a BioSpace survey, almost 70% of respondents are likely to look for a new job in the 12 months. The question is, why? Of those planning to look for a new job, 54% said they wanted new challenges and 42% said they wanted more rewarding opportunities. How about you? Are you ready to lo...